Post-COVID syndrome patients show reduced anti-Spike antibodies compared to COVID-recovered controls, but enhanced IgG4/IgG1 switch after the third vaccine dose
Our results support a differential antibody response in post-COVID versus COVID-recovered patients, which might be relevant for post-COVID syndrome treatment, including appropriate recall vaccination strategies for the still-circulating SARS-CoV-2.
Authors
- Patricia Marín‐García (ORCID: https://orcid.org/0000-0002-2168-6668)
- Narcisa Martı́nez-Quiles (ORCID: https://orcid.org/0000-0002-0366-6591)
- Isabel G. Azcárate (ORCID: https://orcid.org/0000-0003-4545-1254)
- José R. Regueiro (ORCID: https://orcid.org/0000-0001-8442-7762)
- Alba González-Escalada
- Nineth E. Rossi
- Balbino Alarcón (ORCID: https://orcid.org/0000-0001-7820-1070)
- José M. Bautista (ORCID: https://orcid.org/0000-0001-8926-881X)
- Javier Benítez-Cruz
- Oscar G. Hervás
Institutions
- Universidad Complutense de Madrid (ES)
- Universidad Rey Juan Carlos (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Centro de Biología Molecular Severo Ochoa (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1670324
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Comunidad de Madrid